News from mast therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 19, 2014, 16:15 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors.  Dr....

Jun 16, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study...

May 05, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Reports First Quarter 2014 Financial Results

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2014. During the period, the...

Apr 14, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in an ex vivo study conducted at Loyola University Medical Center, MST-188...

Mar 26, 2014, 08:15 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013. "2013 was...

Mar 26, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in...

Mar 11, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected...

Feb 27, 2014, 14:18 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.

Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product...

Feb 25, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd

Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen...

Feb 24, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, consistent with its prior guidance, it has initiated international enrollment...

Feb 18, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study

Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 (low dose...

Feb 10, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.

Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc....

Jan 08, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided an update on the status of EPIC, its pivotal phase 3 study of MST-188 in sickle cell...

Jan 07, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics To Present At The OneMedForum Emerging Company Finance Conference On January 14

Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the...

Jan 06, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Announces Positive Data In Model Of Heart Failure

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188...

Nov 26, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the...

Nov 13, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia

Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the U.S. Food and Drug Administration (FDA) has designated MST-188 for the...

Nov 04, 2013, 08:00 ET

Mast Therapeutics Reports Third Quarter 2013 Financial Results

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended September 30, 2013. Brian M. Culley, Chief...

Oct 01, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics To Present At The 12th Annual BIO Investor Forum On October 8

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the...

Sep 30, 2013, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2

Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Leerink...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge